Pembrolizumab/Chemo Gets EU Recommendation in Resectable NSCLC
February 23rd 2024The European Medicine Agency’s Committee for Medicinal Products for Human Use’s recommendation of approving pembrolizumab plus chemotherapy in resectable non–small cell lung cancer is based on results from the KEYNOTE-671 trial.
Pembrolizumab/Chemo Receives European Approval in First-Line GI Cancers
December 18th 2023In Europe, pembrolizumab is now available as a treatment in combination with fluoropyrimidine-/platinum-containing chemotherapy for HER2-negative gastric or GEJ adenocarcinoma, as well as in combination with gemcitabine/cisplatin for locally advanced biliary tract carcinoma.